David Raben - 12 Sep 2024 Form 3 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role
Chief Medical Officer
Signature
/s/ Lara Meisner, Attorney-in-Fact
Issuer symbol
BCAX
Transactions as of
12 Sep 2024
Net transactions value
$0
Form type
3
Filing time
12 Sep 2024, 21:15:45 UTC
Next filing
10 Oct 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BCAX Common Stock 35,497 12 Sep 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BCAX Stock Option (Right to Buy) 12 Sep 2024 Common Stock 150,870 $3.79 Direct F1
holding BCAX Stock Option (Right to Buy) 12 Sep 2024 Common Stock 70,319 $3.79 Direct F2
holding BCAX Stock Option (Right to Buy) 12 Sep 2024 Common Stock 134,892 $5.45 Direct F3
holding BCAX Stock Option (Right to Buy) 12 Sep 2024 Common Stock 216,368 $9.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
F3 The shares underlying this option vest in sixteen equal quarterly installments following December 14, 2023, subject to the Reporting Person's continued service on each such vesting date.
F4 The shares underlying this option vest in sixteen equal quarterly installments following August 6, 2024, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney